Investigational drug · Phase 2
AST-3424
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for HCC - Hepatocellular Carcinoma, Advanced Solid Tumors, Hepatocellular Carcinoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Dec 30, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "AST-3424"
First trial start
2019
Sep 3, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AST-3424", any sponsor or status.
Conditions studied
As listed on its trial records.
- HCC - Hepatocellular Carcinoma
- Advanced Solid Tumors
- Hepatocellular Carcinoma
Approved drugs for the same conditions: Liver cancer (hepatocellular carcinoma) · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "AST-3424" as an intervention, largest first.
Zhejiang Hisun Pharmaceutical Co. Ltd.Industry
NCT07310173 · 75 participants (planned) · Start Jan 1, 2026 · Primary completion Oct 1, 2027
Drug: AST-3424; Regorafenib Tablets · For: HCC - Hepatocellular Carcinoma
Sites: Nanjing, China
- Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)Active, not recruiting
SWOG Cancer Research NetworkResearch network
NCT04315324 · 67 participants (planned) · Start Feb 8, 2021 · Primary completion Oct 28, 2025
Drug: AKR1C3-activated Prodrug AST-3424 · For: Recurrent T Acute Lymphoblastic Leukemia; Refractory T Acute Lymphoblastic Leukemia; Refractory T Lymphoblastic Lymphoma and 1 more
Sites: Birmingham, Alabama; Kingman, Arizona; Little Rock, Arkansas · 163 sites in all
- A Phase I/II Study of AST-3424 in Subjects With Advanced Solid TumorsActive, not recruiting
Ascentawits Pharmaceuticals, LtdIndustry
NCT06239155 · 51 participants (planned) · Start Sep 3, 2019 · Primary completion Nov 30, 2025
Drug: AST-3424 · For: Advanced Solid Tumors; Hepatocellular Carcinoma
Sites: Guangzhou, China; Zhengzhou, China; Nanjing, China · 7 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Enhanced pharmacological activities of AKR1C3-activated prodrug AST-3424 in cancer cells with defective DNA repair.
Meng F, Qi T, Liu X, et al. · Int J Cancer 2025
- Erratum: A novel selective AKR1C3-activated prodrug AST-3424/OBI-3424 exhibits broad anti-tumor activity.
Meng F, Li WF, Jung D, et al. · Am J Cancer Res 2023
- A novel AKR1C3 specific prodrug AST-3424 and its combination therapy in hepatocellular carcinoma.
Xun C, Zhang Y, Zheng X, et al. · J Pharmacol Sci 2023
- The In-Vitro Antitumor Effects of AST-3424 Monotherapy and Combination Therapy With Oxaliplatin or 5-Fluorouracil in Primary Liver Cancer.
Zhang Y, Qin S, Chao J, et al. · Front Oncol 2022
- A novel selective AKR1C3-activated prodrug AST-3424/OBI-3424 exhibits broad anti-tumor activity.
Meng F, Li WF, Jung D, et al. · Am J Cancer Res 2021
Also in development for HCC - Hepatocellular Carcinoma
- SintilimabIBI308Phase 321 trials
Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma
- SYS6043Phase 35 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Advanced Solid Tumors, Advanced/Metastatic Solid Tumors, HCC - Hepatocellular Carcinoma
- SYS6090Phase 23 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HCC - Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Small Cell Lung Cancer
- Decoy20Phase 21 trial
Indaptus Therapeutics, Inc · Solid Tumor, Adult, HCC - Hepatocellular Carcinoma, CRC (Colorectal Cancer)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.